Inocras
Private Company
Funding information not available
Overview
Inocras is a commercial-stage diagnostics and services company leveraging whole genome sequencing (WGS) and advanced bioinformatics to provide actionable insights in oncology and rare disease. Its core offerings include CancerVision for solid tumors, MRDVision for minimal residual disease detection, and RareVision for rare genetic disorders, all delivered through a CAP/CLIA lab with a two-week turnaround. The company serves patients, healthcare providers, and researchers, positioning itself at the intersection of clinical diagnostics and genomic research services.
Technology Platform
Clinical whole genome sequencing (WGS) integrated with advanced AI and bioinformatics for variant detection (SNV, Indel, SV, CNV, non-coding) and biomarker analysis (TMB, MSI, HRD). Includes a tumor-informed, whole-genome ctDNA platform for minimal residual disease detection.
Opportunities
Risk Factors
Competitive Landscape
Inocras competes in the crowded clinical genomics market against large players like Foundation Medicine (Roche) and Guardant Health in oncology, and Invitae and GeneDx in rare disease. Its differentiation is its focus on clinical whole genome sequencing as a primary method, rather than exome or panels, claiming to uncover more complex variants.